Plasma Chromogranin A in Patients with MEN I and Pancreatic Endocrine Tumors
Introduction: Circulating chromogranin A(CgA) is considered a useful marker for gastroenteropancreatic endocrine tumors. Data on its pattern in MEN-1 patients with non-functioning pancreatic tumors(NFPT) are scant.
Aim(s): To evaluate the usefulness of plasma CgA determination in the clinical assessment of MEN 1.
Materials and methods: Between January 2005 and December 2010 plasma CgA was assayed in 54 MEN-1 patients. Pancreatic tumors (PT) occurred in 33 patients (14 functioning tumors, 19 NFPT). All patients had a complete hormonal profile and imaging studies, including CT, MRI, Octreoscan, and endoscopic ultrasonography in selected cases. CgA was measured by ELISA (DAKO A/S).
Conference: 8th Annual ENETSConcerence (2011)
To read the full abstract, please log into your ENETS Member account.